Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Medicine. 2010;7:e1000236.
Event rates in trials of patients with type 2 diabetes. Journal of the American Medical Association (JAMA). 2010;303:732; author reply 733..
Management of chronic kidney disease in Australian general practice (the AusHEART Study). 46th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology. 2010.
Oral disease and subsequent cardiovascular disease in people with type 2 diabetes: a prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2010;53:2320-7.
Protection against cardiovascular and renal disease in type 2 diabetes: ADVANCEs in the control of blood pressure using Preterax and Diamicron MR. Issue IV. France: Wolters Kluwer Health France; 2010.
Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk. BMC Public Health. 2010;10:458.
Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine. 2010;363:1410-8.
[Symposium] Trials of the cardiovascular polypill. In: 21st Great Wall International Congress of Cardiology. 21st Great Wall International Congress of Cardiology. Beijing, China; 2010..
The discrimination of dyslipidaemia using anthropometric measures in ethnically diverse populations of the Asia-Pacific Region: the Obesity in Asia Collaboration. Obesity Reviews. 2010;11:127-36.
The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Research and Clinical Practice. 2010;89:126-33.